Close Menu

NEW YORK (GenomeWeb) – Protea Biosciences has licensed a mass spectrometry-based technology from Yale University aimed at improving diagnosis of melanoma.

The Morgantown, West Virginia-based firm is developing a test that will use proteomic mass spec imaging (MSI), pioneered by Yale Dermatology Professor Rossitza Lazova and Protea's Erin Seeley.

According to the partners, the imaging technology allows researchers to identify hundreds of specific proteins in tissue, which can help distinguish between cancerous melanomas and benign moles, also called melanocytic nevi.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Mainichi reports that 43 percent of Japanese individuals said they did not want to eat agricultural products that had been modified using gene-editing tools.

Two US Department of Agriculture research departments are moving to the Kansas City area, according to the Washington Post.

Slate's Jane Hu compares some at-home genetic tests to astrology.

In PLOS this week: analysis of polygenic risk scores for skin cancer, chronic pain GWAS, and more.